<DOC>
	<DOCNO>NCT02520102</DOCNO>
	<brief_summary>Primary Objective : Measure proportion patient develop bind neutralize antibody blood treatment sargramostim follow induction/reinduction chemotherapy . Secondary Objectives : - Assess time treatment antibody develop level antibody measure first dose . - Measure level immunoglobulin protein . - Assess impact immune response safety duration low white blood cell count .</brief_summary>
	<brief_title>Open Label Study Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy Acute Myelogenous Leukemia</brief_title>
	<detailed_description>The total study duration participant 6 month 1st dose sargramostim antibody level return baseline 24 month antibody test positive month 6 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<criteria>Inclusion criterion : Able provide inform consent . Newly diagnose acute myeloid leukemia ( AML ) treat standard care induction chemotherapy per local policy . Patients 55 70 year age ( inclusive ) . Negative serum pregnancy test within 30 day prior receive first dose induction chemotherapy female participant &lt; 2 year postmenopausal childbearing potential agree begin continue use adequate method contraception . Exclusion criterion : Prior treatment sargramostim leukocyte growth factor ( LGF ) product . Prior myelodysplastic syndrome ( MDS ) . Known central nervous system ( CNS ) leukemic involvement diagnose cytologic finding cerebrospinal fluid and/or compute tomography ( CT ) magnetic resonance imaging ( MRI ) . Out range ( &gt; 2x normal ) laboratory value . Clinically important medical condition unrelated AML determine Investigator . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 . Bone marrow blast â‰¥5 % marrow examination follow induction reinduction chemotherapy . History allergy yeast product , recombinant human granulocyte/macrophagecolonystimulating factor , component sargramostim . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>